Earnings Material +

Trulieve Reports Profitable First Quarter 2026 Results Bolstered by Margins and Cash Flow Generation

Trulieve Posts Profit as Cannabis Rescheduling Lifts Margins

By The Northwire Desk — AI Analysis May 07, 2026 · 06:15 TRUL · 13.63 Trulieve Cannabis Corp.

Executive Summary

Event: Q1 2026 Earnings Release (May 7, 2026).
Financials: Revenue $287 million (down 4% YoY), Net Income $2 million (vs. loss of $33.8 million in Q1 2025), Adjusted EBITDA $100 million (35% margin).
Cash Flow: Operating cash flow $56 million, Free Cash Flow $42 million. Cash position $353 million.
Regulatory: Filed DEA registration applications for 206 retail locations following medical marijuana rescheduling to Schedule III.
Operations: Opened 7 new dispensaries in Florida (total 240). Expanded rewards program to 1 million members.
Financing: Closed $60 million tranche of senior secured notes due 2030 (part of $200 million total issuance).

Material Impact

Profitability Inflection: The transition from a net loss of $33.8 million in Q1 2025 to a net income of $2 million in Q1 2026 is a critical inflection point for the company and the sector. GAAP profitability validates operational discipline and margin expansion.
Regulatory Tailwind: The filing of DEA applications capitalizes on the April 23, 2026 rescheduling news. This removes Section 280E tax burdens for medical operations, directly supporting future net income margins beyond Q1 levels.
Revenue Concern: Revenue declined 4% year-over-year ($298M to $287M). While profitability improved, top-line contraction suggests market saturation or pricing pressure in core Florida markets despite new store openings.
Debt Cost: The company issued $200 million in senior secured notes at 10.5%. While this refinances older debt and extends maturity, the high interest rate ($21 million annual expense) creates a fixed cost burden that must be covered by operating cash flow.
Market Reaction: Stock price has rallied from ~$7.05 (March low) to $13.63 (May 6), reflecting pricing in of the regulatory and earnings catalysts.

TRUL · Price

Company Overview

Overview: Trulieve is a vertically integrated cannabis operator primarily focused on the U.S. medical market, with significant presence in Florida.
Flagship Project: Florida Medical Cannabis Network. Operates 240 dispensaries with over 3.5 million square feet of cultivation/processing capacity.
Expansion: Recently secured conditional license for Texas (high population potential) and expanding retail footprint within Florida.
Brand Portfolio: In-house brands include Co2lors, Cultivar Collection, Modern Flower; exclusive partners include Alien Labs, Binske.

More from Trulieve Cannabis Corp.